Efficacy and use of currently available SARS-CoV-2 vaccines in Germany
This statement has been updated for the 4th time as of 12.04. 2021; the first version was prepared by the German Society for Paediatric Infectiology and the German Society for Infectiology on 17.02.2021. The updates concern the recommendations of the Robert Koch Institute on the age limit (60 years and older) for the administration of the AstarZeneca vaccine and the recommendation to administer a different vaccine to younger persons for the second vaccination until further notice (April 2021) as well as information on the side effects of the AstraZeneca vaccine from statements by the Society for Thrombosis and Haemostasis Research and the German Society for Neurology as well as the reference to the approval of the Johnson&Johnson vaccine (March 2021). This statement is supported by 26 scientific medical societies and the Association of the Scientific Medical Societies (AWMF).